{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:48:41Z","timestamp":1774907321217,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RRC_2024"],"award-info":[{"award-number":["RRC_2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gene.2025.149536","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:48:29Z","timestamp":1746312509000},"page":"149536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacogenetic pilot study of CYP2D6 and CYP1A2 genes in Italian patients with non-dystrophic myotonia and myotonic dystrophy treated with mexiletine"],"prefix":"10.1016","volume":"960","author":[{"given":"Raffaella","family":"Brugnoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Moresco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Gallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Grandis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.gene.2025.149536_b0005","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: Precision Medicine and Drug Response","volume":"92","author":"Weinshilboum","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.gene.2025.149536_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-030-24100-1_2","article-title":"Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer","volume":"1168","author":"Morganti","year":"2019","journal-title":"Adv Exp Med Biol."},{"issue":"6","key":"10.1016\/j.gene.2025.149536_b0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/genes11060679","article-title":"Pharmacogenomics and Personalized Medicine","volume":"11","author":"Cecchin","year":"2020","journal-title":"Genes (basel)"},{"issue":"10","key":"10.1016\/j.gene.2025.149536_b0020","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00439-012-1221-z","article-title":"The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era","volume":"131","author":"Ritchie","year":"2012","journal-title":"Hum Genet."},{"key":"10.1016\/j.gene.2025.149536_b0025","doi-asserted-by":"crossref","unstructured":"Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81:358.e367. 2. Doi: 10.1136\/jnnp.2008.158261.","DOI":"10.1136\/jnnp.2008.158261"},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol Clin."},{"issue":"6","key":"10.1016\/j.gene.2025.149536_b0035","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/cells10061521","article-title":"Ion Channel Gene Mutations Causing Skeletal Muscle Disorders: Pathomechanisms and Opportunities for Therapy","volume":"10","author":"Maggi","year":"2021","journal-title":"Cells."},{"issue":"7","key":"10.1016\/j.gene.2025.149536_b0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jval.2021.02.004","article-title":"Cost-based price calculation of mexiletine for non-dystrophic myotonia","volume":"24","author":"van den Berg","year":"2021","journal-title":"Value Health."},{"key":"10.1016\/j.gene.2025.149536_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1195778","article-title":"Characterization of complex structural variation in the CYP2D6-CYP2D7-CYP2D8 gene loci using single-molecule long-read sequencing","volume":"14","author":"Turner","year":"2023","journal-title":"Front Pharmacol."},{"issue":"12","key":"10.1016\/j.gene.2025.149536_b0050","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/14656566.2023.2223964","article-title":"Indications for mexiletine in the new ESC guidelines and beyond","volume":"24","author":"Vamos","year":"2023","journal-title":"Expert Opin Pharmacother."},{"issue":"12","key":"10.1016\/j.gene.2025.149536_b0055","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/14737159.2023.2288258","article-title":"Diagnostics in skeletal muscle channelopathies","volume":"23","author":"Vicino","year":"2023","journal-title":"Expert Rev Mol Diagn."},{"key":"10.1016\/j.gene.2025.149536_b0060","doi-asserted-by":"crossref","unstructured":"Matthews E, Fialho D, Tan SV, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain. 2010;133(1):9-22. 4. Doi: 10.1093\/brain\/awp294.","DOI":"10.1093\/brain\/awp294"},{"issue":"6","key":"10.1016\/j.gene.2025.149536_b0065","first-page":"45","article-title":"Cellular hyper-excitability caused by mutations that alter the activation process of voltage-gated sodium channels","volume":"17","author":"Amarouch","year":"2015","journal-title":"Front Physiol."},{"issue":"9","key":"10.1016\/j.gene.2025.149536_b0070","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/a-0635-8285","article-title":"Dystrophic and non-dystrophic myotonias","volume":"86","author":"Montagnese","year":"2018","journal-title":"Fortschr Neurol Psychiatr."},{"key":"10.1016\/j.gene.2025.149536_b0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/82.1.81","article-title":"The treatment of myotonia: a controlled clinical trial","volume":"82","author":"Leyburn","year":"1959","journal-title":"Brain."},{"key":"10.1016\/j.gene.2025.149536_b0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ana.410030614","article-title":"Effects of acetazolamide on myotonia","volume":"3","author":"Griggs","year":"1978","journal-title":"Ann Neurol"},{"key":"10.1016\/j.gene.2025.149536_b0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000115546","article-title":"Carbamazepine versus diphenylhydantoin in the treatment of myotonia","volume":"22","author":"Sechi","year":"1983","journal-title":"Eur Neurol."},{"key":"10.1016\/j.gene.2025.149536_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1651-2227.1992.tb12271.x","article-title":"Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen\u2019s disease) successfully treated with mexiletine","volume":"81","author":"Ceccarelli","year":"1992","journal-title":"Acta Paediatr."},{"issue":"18","key":"10.1016\/j.gene.2025.149536_b0095","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology."},{"issue":"100","key":"10.1016\/j.gene.2025.149536_b0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.expneurol.2014.02.023","article-title":"Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs","volume":"255","author":"Desaphy","year":"2014","journal-title":"Exp Neurol"},{"issue":"22","key":"10.1016\/j.gene.2025.149536_b0105","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.gene.2025.149536_b0110","first-page":"e228","article-title":"Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind","volume":"96","author":"Heatwole","year":"2021","journal-title":"Placebo-Controlled Trial. Neurology."},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12883-021-02491-3","article-title":"Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel","volume":"21","author":"Chapman","year":"2021","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.gene.2025.149536_b0120","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1212\/CPJ.0000000000001073","article-title":"Long-term Safety and Efficacy of Mexiletine in Myotonic Dystrophy Types 1 and 2","volume":"11","author":"Mousele","year":"2021","journal-title":"Neurol Clin Pract."},{"key":"10.1016\/j.gene.2025.149536_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102329","article-title":"Drug repurposing in skeletal muscle ion channelopathies","volume":"68","author":"Altamura","year":"2023","journal-title":"Curr Opin Pharmacol."},{"issue":"13","key":"10.1016\/j.gene.2025.149536_b0130","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA."},{"key":"10.1016\/j.gene.2025.149536_b0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fneur.2020.00300","article-title":"Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias","volume":"11","author":"Modoni","year":"2020","journal-title":"Front Neurol."},{"issue":"5","key":"10.1016\/j.gene.2025.149536_b0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199937050-00002","article-title":"Clinical pharmacokinetics of mexiletine","volume":"37","author":"Labb\u00e9","year":"1999","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"PharmVar Steering Committee.The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cpt.1643","article-title":"PharmVar GeneFocus: CYP2D6","volume":"107","author":"Nofziger","year":"2020","journal-title":"Clin Pharmacol Ther."},{"issue":"11","key":"10.1016\/j.gene.2025.149536_b0155","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/genes11111295","article-title":"A Review of the Important Role of CYP2D6 in Pharmacogenomics","volume":"11","author":"Taylor","year":"2020","journal-title":"Genes (basel)"},{"issue":"11","key":"10.1016\/j.gene.2025.149536_b0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5\u20136","key":"10.1016\/j.gene.2025.149536_b0165","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00228-003-0656-5","article-title":"Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers","volume":"59","author":"Otani","year":"2003","journal-title":"Eur J Clin Pharmacol."},{"issue":"2","key":"10.1016\/j.gene.2025.149536_b0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab Rev."},{"key":"10.1016\/j.gene.2025.149536_b0175","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nmd.2005.07.002","article-title":"Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist","volume":"15","author":"Hammar\u00e9n","year":"2005","journal-title":"Neuromuscul Disord."},{"issue":"11","key":"10.1016\/j.gene.2025.149536_b0180","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.gene.2025.149536_b0185","doi-asserted-by":"crossref","unstructured":"Brugnoni R, Maggi L, Canioni E,Verde F, Gallone A, Ariatti A, Filosto M, Petrelli C, Logullo FO, Esposito M, Ruggiero L, Tonin P, Riguzzi P, Pegoraro E, Torri F, Ricci G, Siciliano G, Silani V, et al. Next-generation sequencing application to investigate skeletal muscle channelopathies in a large cohort of Italian patients. Neuromuscul Disord 2021;31(4):336-347. ttps:\/\/doi.org\/10.1016\/j.nmd.2020.12.003.","DOI":"10.1016\/j.nmd.2020.12.003"},{"key":"10.1016\/j.gene.2025.149536_b0190","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics."},{"key":"10.1016\/j.gene.2025.149536_b0195","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with BurrowsWheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics."},{"key":"10.1016\/j.gene.2025.149536_b0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat Genet."},{"issue":"2","key":"10.1016\/j.gene.2025.149536_b0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (austin)."},{"issue":"21","key":"10.1016\/j.gene.2025.149536_b0210","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/bioinformatics\/bts526","article-title":"A robust model for read count data in exome sequencing experiments and implications for copy number variant calling","volume":"28","author":"Plagnol","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.gene.2025.149536_b0215","doi-asserted-by":"crossref","unstructured":"Lee, S-B. MM, Patterson K, McGee S, Dalton R, EL, A, Thummel KE, DA. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med. 2019;21(2):361-372. Doi: 10.1038\/s41436-018-0054-0.","DOI":"10.1038\/s41436-018-0054-0"},{"issue":"6","key":"10.1016\/j.gene.2025.149536_b0220","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/cpt.1552","article-title":"Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences","volume":"106","author":"Lee","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.gene.2025.149536_b0225","article-title":"Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes","volume":"26;9(1):828","author":"Numanagi\u0107","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1101\/gr.277075.122","article-title":"An efficient genotyper and star-allele caller for pharmacogenomics","volume":"33","author":"Hari","year":"2023","journal-title":"Genome Res"},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther."},{"issue":"5","key":"10.1016\/j.gene.2025.149536_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101050","article-title":"Quantitative proteomics identifies the universally conserved ATPase Ola1p as a positive regulator of heat shock response in Saccharomyces cerevisiae","volume":"297","author":"Dannenmaier","year":"2021","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03195622","article-title":"Isolation, sequence identification and tissue expression profiles of 3 novel porcine genes: ASPA, NAGA, and HEXA","volume":"49","author":"Shu","year":"2008","journal-title":"J Appl Genet."},{"issue":"24","key":"10.1016\/j.gene.2025.149536_b0250","doi-asserted-by":"crossref","first-page":"21431","DOI":"10.1074\/jbc.M201708200","article-title":"Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics","volume":"277","author":"Daugherty","year":"2002","journal-title":"J Biol Chem."},{"issue":"2","key":"10.1016\/j.gene.2025.149536_b0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jimd.12584","article-title":"Pathogenic variants of the coenzyme A biosynthesis-associated enzyme phosphopantothenoyl-cysteine decarboxylase cause autosomal-recessive dilated cardiomyopathy","volume":"46","author":"Bravo-Alonso","year":"2023","journal-title":"J Inherit Metab Dis."},{"issue":"4","key":"10.1016\/j.gene.2025.149536_b0260","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ajhg.2018.08.013","article-title":"Bi-allelic Mutations in NDUFA6 Establish Its Role in Early-Onset Isolated Mitochondrial Complex I Deficiency.Am","volume":"103","author":"Alston","year":"2018","journal-title":"J Hum Genet"},{"key":"10.1016\/j.gene.2025.149536_b0265","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1432-1033.1994.tb19954.x","article-title":"Purification, cDNA cloning and heterologous expression of human phosphomannose isomerase","volume":"219","author":"Proudfoot","year":"1994","journal-title":"Europ J Biochem"},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gene.2025.149536_b0275","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.26887","article-title":"Guidelines on clinical presentation and management of non-dystrophic myotonias","volume":"62","author":"Stunnenberg","year":"2020","journal-title":"Muscle Nerve."},{"issue":"7","key":"10.1016\/j.gene.2025.149536_b0280","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00424-020-02376-3","article-title":"Skeletal muscle ClC-1 chloride channels in health and diseases","volume":"472","author":"Altamura","year":"2020","journal-title":"Pflugers Arch"},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0285","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.0306-5251.2001.01411.x","article-title":"Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes","volume":"52","author":"Senda","year":"2001","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"10.1016\/j.gene.2025.149536_b0290","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12695","article-title":"Interrogation of CYP2D6 structural variant alleles improves the correlation between CYP2D6 genotype and CYP2D6-mediated metabolic activity","volume":"13","author":"Dalton","year":"2020","journal-title":"Clin Transl Sci."},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0295","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/pharmaceutics14030532","article-title":"CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity","volume":"14","author":"Fekete","year":"2022","journal-title":"Pharmaceutics."},{"issue":"2","key":"10.1016\/j.gene.2025.149536_b0300","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/chir.10307","article-title":"Stereospecific synthesis of \u201cpara-hydroxymexiletine\u201d and sodium channel blocking activity evaluation","volume":"16","author":"Catalano","year":"2004","journal-title":"Chirality."},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0305","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjp.0706867","article-title":"Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents","volume":"149","author":"De Bellis","year":"2006","journal-title":"Br J Pharmacol."},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0310","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1021\/jm201197z","article-title":"Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels","volume":"55","author":"Catalano","year":"2012","journal-title":"J Med Chem."},{"issue":"22","key":"10.1016\/j.gene.2025.149536_b0315","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1212\/WNL.0000000000002721","article-title":"Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation","volume":"86","author":"Desaphy","year":"2016","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.gene.2025.149536_b0320","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JND-200582","article-title":"Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine","volume":"8","author":"Desaphy","year":"2021","journal-title":"J Neuromuscul Dis."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925003245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925003245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:11:37Z","timestamp":1747195897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111925003245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":64,"alternative-id":["S0378111925003245"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149536","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic pilot study of CYP2D6 and CYP1A2 genes in Italian patients with non-dystrophic myotonia and myotonic dystrophy treated with mexiletine","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149536"}}